Should chronic heart failure patients with reduced left-ventricular ejection fraction receive angiotensin-receptor blockers?
Pitt
Bertram
B
University of Michigan School of Medicine, Ann Arbor, MI 48109, USA. Bpitt@umich.edu
D000368:Aged; D047228:Angiotensin II Type 1 Receptor Blockers / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use*; D001713:Biphenyl Compounds; D002423:Cause of Death / Q000639:trends; D004311:Double-Blind Method; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D006801:Humans; D007391:International Cooperation; D008297:Male; D013318:Stroke Volume / Q000187:drug effects* / Q000502:physiology; D015996:Survival Rate; D013777:Tetrazoles / Q000627:therapeutic use*; D016896:Treatment Outcome; D016277:Ventricular Function, Left / Q000187:drug effects* / Q000502:physiology
D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D013777:Tetrazoles; C081643:candesartan